ArticleInterdisciplinary cardiovascular and thoracic surgery2024
Impact of neoadjuvant therapy on angioplastic lobectomy: a retrospective study.
Article in Interdisciplinary cardiovascular and thoracic surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe efficacy of neoadjuvant therapy (NT) prior to angioplastic lobectomy (AL) in non-small cell lung cancer is unclear. This study assessed its impact on morbidity, mortality and 5-year survival.
methodsWe retrospectively analysed 114 patients who underwent AL at 2 tertiary centres from January 2000 to December 2020. Comparisons were made between patients who received NT and those who did not.
resultsAmong the patients, 78 (68.4%) underwent upfront surgery, and 36 (31.6%) received NT. There were no significant differences in postoperative complications (46.2% vs 31.6%, P = 0.42) or mortality rates (0% vs 3.8%, P = 0.55). Pathological upstaging differed significantly (37.2% vs 5.6%, P = 0.0008). Five-year survival rates were comparable (54% vs 38%, P = 0.3).
conclusionsNeoadjuvant therapy does not adversely affect morbidity, arterial repair complications or mortality in AL. There are no survival differences at 5 years. AL remains a safe option following NT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.